Different Response to the Long-Acting Somatostatin Analogues Lanreotide and Octreotide in a Patient with a Malignant Carcinoid

Publisher： Karger

E-ISSN： 1423-0232|60|2|141-145

ISSN： 0030-2414

Source： Oncology, Vol.60, Iss.2, 2001-02, pp. : 141-145

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Pilot Study of Long-Acting Octreotide for Symptomatic Malignant Ascites

By  

Oncology, Vol. 82, Iss. 6, 2012-05 ,pp. : 315-320

Karger

Access to resources Recommend Favorite

Octreotide long‐acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: A population‐based analysis

By  

CANCER, Vol. 120, Iss. 13, 2014-07 ,pp. : 2039-2049

John Wiley & Sons Inc

Access to resources Recommend Favorite

Double benefit of long‐acting somatostatin analogs in a patient with coexistence of acromegaly and ulcerative colitis

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 41, Iss. 5, 2016-10 ,pp. : 559-562

John Wiley & Sons Inc

Access to resources Recommend Favorite

Everolimus in combination with octreotide long‐acting repeatable in a first‐line setting for patients with neuroendocrine tumors: An ITMO group study

By  

CANCER, Vol. 120, Iss. 16, 2014-08 ,pp. : 2457-2463

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐Acting Reversible Contraception for Adolescents

By  

NURSING FOR WOMENS HEALTH, Vol. 19, Iss. 3, 2015-06 ,pp. : 253-259

John Wiley & Sons Inc

Access to resources Recommend Favorite